Amyotrophic Lateral Sclerosis Market Set for Strong Expansion Through 2036 Amid Rising Investment Interest - DelveInsight

To strategically aid Amyotrophic Lateral Sclerosis companies developing drugs for Amyotrophic Lateral Sclerosis, DelveInsight launched a report titled as "Amyotrophic Lateral Sclerosis Market Insight, Epidemiology And Market Forecast - 2036". This comprehensive report delves into epidemiology based market analysis, providing a roadmap for success in the dynamic landscape of Amyotrophic Lateral Sclerosis market.

To Know in detail about the Amyotrophic Lateral Sclerosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Amyotrophic Lateral Sclerosis Market Forecast
https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Key Highlights from Amyotrophic Lateral Sclerosis market Report:
• Among the 7MM regions, the United States held the largest market share, with an estimated market size of approximately USD 850 million in 2025.
• In May 2026, Coya Therapeutics (NASDAQ: COYA), a clinical-stage biotechnology company developing biologics designed to improve regulatory T cell (Treg) function in neurodegenerative diseases, announced that the U.S. FDA has granted Fast Track Designation to COYA 302 for the treatment of amyotrophic lateral sclerosis (ALS). COYA 302 is the company's proprietary investigational biologic combination therapy featuring a dual mechanism of action.
• In May 2026, QurAlis' Phase II findings strengthened support for a genetic-based strategy in treating sporadic amyotrophic lateral sclerosis (ALS). In 2023, Biogen's Qalsody received FDA approval for a rare hereditary form of ALS, while QurAlis recently shared interim Phase II results highlighting the potential of its therapy to address a broader ALS patient population. The latest wave of ALS treatment candidates is beginning to generate meaningful clinical outcomes. Although Corcept Therapeutics reported mixed mid-stage trial data last week, QurAlis demonstrated encouraging results, showing a significant slowing in the progression of the devastating neurodegenerative disorder.
• In April 2026, Shionogi announced that updated analyses of RADICAVA ORS (edaravone) will be showcased at the American Academy of Neurology (AAN) 2026 conference, highlighting the use of digital health technologies and potential prognostic biomarkers to enhance disease monitoring and track progression in ALS.
• In early 2026, Clene Nanomedicine announced encouraging biomarker and survival results for CNM-Au8 and revealed its intention to pursue accelerated approval from the U.S. FDA, underscoring its potential as a disease-modifying treatment for amyotrophic lateral sclerosis (ALS).
• In February 2026, the U.S. Department of Defense's ALS Research Program (ALSRP) introduced new funding initiatives to encourage innovative, high-impact research focused on improving outcomes and advancing potential therapeutic breakthroughs for amyotrophic lateral sclerosis (ALS).
• In September 2025, Amylyx Pharmaceuticals announced that, following recent discussions with the FDA, the company received permission to submit a new drug application (NDA) for its investigational ALS therapy, AMX0035, based on data from the Phase II CENTAUR trial. Earlier, in April 2021, the FDA had requested that Amylyx conduct an additional Phase III study before seeking approval for AMX0035. In response, the company planned the global Phase III PHOENIX trial involving approximately 600 participants, with completion anticipated in Q4 2023.
• In August 2025, Coya Therapeutics announced that the FDA has accepted its Investigational New Drug (IND) application for COYA 302, an immunomodulatory biologic being developed for the treatment of amyotrophic lateral sclerosis (ALS).
• In August 2025, Neurizon Therapeutics announced that manufacturing has commenced for the first registration batch of NUZ-001 tablets, its lead therapeutic candidate for amyotrophic lateral sclerosis (ALS). This milestone underpins upcoming pivotal studies, regulatory filings, and potential commercial production, representing a key step toward global market access.
• In August 2025, Neurizon Therapeutics reported that the U.S. FDA is expected to issue a decision by October 3, 2025, regarding its Clinical Hold Complete Response (CHCR) submission for NUZ-001, the company's lead investigational treatment for amyotrophic lateral sclerosis (ALS).
• In July 2025, AB Science announced that its confirmatory Phase 3 trial of masitinib in amyotrophic lateral sclerosis (ALS), known as study AB23005, has been authorized by the initial group of European countries Spain, Greece, and Slovenia through the CTIS procedure, following EMA validation and earlier FDA clearance. This approval enables the company to initiate the registration study in both Europe and the United States.
• In July 2025, Neurizon Therapeutics has submitted a formal response to the FDA to address the clinical hold placed on its Investigational New Drug (IND) application for NUZ-001, its lead therapeutic candidate for amyotrophic lateral sclerosis (ALS).
• In July 2025, NKGen Biotech has received FDA authorization to implement an Expanded Access Program (EAP) allowing the use of its NK cell therapy, troculeucel, across multiple neurodegenerative disorders including Alzheimer's, Parkinson's, ALS, MSA, PSP, FTD, MS, and Lewy body dementia beyond its ongoing Phase 2a study in patients with moderate-stage Alzheimer's disease.
• In July 2025, Klotho Neurosciences announced that the FDA has granted Orphan Drug Designation to KLTO-202 (s-KL-AAV.myo), its secreted-Klotho gene therapy candidate, for the treatment of amyotrophic lateral sclerosis (ALS).
• In June 2025, Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) announced that the FDA has awarded Fast Track designation to AMX0114, an investigational antisense oligonucleotide designed to target calpain-2 for the treatment of amyotrophic lateral sclerosis (ALS).
• In May 2025, BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) has announced that it has received FDA approval to initiate its Phase 3b clinical trial evaluating NurOwn® for the treatment of amyotrophic lateral sclerosis (ALS).
• In January 2025, The US Food and Drug Administration (FDA) has authorized Zydus Lifesciences to initiate a randomized Phase IIb clinical trial of Usnoflast, its oral NLRP3 inflammasome inhibitor, for the treatment of amyotrophic lateral sclerosis (ALS). This multi-center, double-blind, placebo-controlled study will evaluate the drug's safety, pharmacodynamics, efficacy, and pharmacokinetics in adult ALS patients.
• In January 2025, The US Food and Drug Administration (FDA) has removed the clinical hold on Amylyx Pharmaceuticals' Phase I trial of AMX0114 for amyotrophic lateral sclerosis (ALS). With the hold lifted, Amylyx can now initiate screening, enrollment, and dosing at US sites for the Phase I LUMINA study (NCT06665165). This multi-center, multiple ascending dose trial will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of AMX0114 in 48 ALS patients. Participants will be randomized in a 3:1 ratio to receive either AMX0114 or a placebo via intrathecal injection every four weeks, for up to four doses.
• The market size for ALS in the US was estimated at approximately USD 920 million in 2023, with expectations for growth throughout the forecast period (2024-2036).
• RADICAVA is expected to be the top performer in the current ALS market, with projected revenue reaching USD 923 million in the US by 2036.
• After the setback with RELYVRIO, RADICAVA emerges as the leading contender in the current ALS market and is anticipated to achieve the highest revenue.
• Brainstorm-Cell Therapeutics's NurOwn is pioneering novel treatments for ALS through stem cell and T-cell therapy approaches.
• Transposon Therapeutics' TPN-101 and Ionis Pharmaceuticals' ulefnersen are therapies tailored for specific mutations like C9ORF72 and FUS in ALS.
• By 2036, Masitinib in combination with riluzole is projected to generate the highest revenue among emerging therapies, reaching USD 37 million in Japan.
• Currently, ALS treatments include EXSERVAN (Riluzole oral film), RELYVRIO, QALSODY, RADICAVA (edaravone injection), RADICAVA ORS (edaravone oral suspension), NEUDEXTA, TIGLUTEK, and RILUTEK, along with other symptomatic therapies such as anti-epileptic drugs, opioids, NSAIDs, diuretics, SSRIs, and antidepressants.
• The total prevalent cases of ALS in the 7MM comprised nearly 68,000 in 2025 which are estimated to increase by 2036.
• In the US, among mutation-specific cases of ALS in 2025-including C9ORF72, SOD1, FUS, and others such as TARDBP, OPTN, and ANG, non-mutated or unidentified mutations accounted for the largest proportion, representing approximately 71% of cases.
• Among the EU4 and the UK, among the type-specific cases, nearly 90% cases comprised of sporadic, and around 10% cases comprised of familial in 2025.
• Among the gender-specific cases, nearly 55% cases comprised of males, and nearly 45% cases comprised of females in Japan in 2025.
• Key Amyotrophic Lateral Sclerosis Companies: Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, Alector, GSK, NeuroSense Therapeutics, Biogen, Ionis Pharmaceuticals, Brainstorm Cell Therapeutics, Cytokinetics, Astellas Pharma, Apellis Pharmaceuticals, Clene Nanomedicine Biosciences, AL-S Pharma, MediciNova, and others
• Key Amyotrophic Lateral Sclerosis Therapies: Engensis (VM202), SAR443820/DNL788, TPN-101, Latozinemab (AL001/GSK4527223), PrimeC, Tofersen (BIIB067), ION363, NurOwn (MSC-NTF cells), Reldesemtiv, Pegcetacoplan (APL-2), Gold Nanocrystals/CNM-Au8, AP-101, MN-166 (ibudilast), and others

Amyotrophic Lateral Sclerosis Country based Treatment Overview:
The Amyotrophic Lateral Sclerosis market research report provides current treatment practices, emerging drugs, Amyotrophic Lateral Sclerosis market share of the individual therapies, current and forecasted Amyotrophic Lateral Sclerosis market Size from 2022 to 2036 segmented by seven major markets.
Lou Gehrig's disease, often known as amyotrophic lateral sclerosis (ALS), is a collection of uncommon neurological disorders primarily affecting the nerve cells (neurons) in charge of voluntary muscular movement. Movements like chewing, walking, and talking are produced by voluntary muscles. Since the illness is progressive, the symptoms worsen with time.

Get a Free sample for the Amyotrophic Lateral Sclerosis Market Report:
https://www.delveinsight.com/report-store/amyotrophic-lateral-sclerosis-als-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Amyotrophic Lateral Sclerosis Epidemiology Insights:
The Amyotrophic Lateral Sclerosis epidemiology section offers insights into the past and present patient population affected by the disease, along with predicted trends across seven major countries. It assists in understanding the reasons behind current and anticipated trends by analyzing multiple studies and opinions from key experts.
• In 2023, the US had the highest prevalence of ALS among the 7MM, with approximately 26,000 cases. This number is anticipated to rise throughout the forecast period.
• In 2023, Germany had the highest number of diagnosed ALS cases among the EU4 and the UK, whereas Spain had the fewest cases.
• The primary onset sites for ALS include the bulbar and spinal regions, along with other indeterminate areas. In 2023, spinal onset ALS had the highest number of cases, totaling 15,000, followed by bulbar onset.
• The Amyotrophic Lateral Sclerosis epidemiology based on gender analyzed that males are more affected than females in case of Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis Epidemiology Segmentation:
• Total Prevalence of Amyotrophic Lateral Sclerosis
• Prevalent Cases of Amyotrophic Lateral Sclerosis by severity
• Gender-specific Prevalence of Amyotrophic Lateral Sclerosis
• Diagnosed Cases of Episodic and Chronic Amyotrophic Lateral Sclerosis

Download the report to understand which factors are driving Amyotrophic Lateral Sclerosis epidemiology trends @ Amyotrophic Lateral Sclerosis Epidemiology Forecast
https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Amyotrophic Lateral Sclerosis Drugs and Key Companies
• Engensis (VM202): Helixmith
• SAR443820/DNL788: Sanofi/Denali Therapeutics
• TPN-101: Transposon Therapeutics
• Latozinemab (AL001/GSK4527223): Alector/GSK
• PrimeC: NeuroSense Therapeutics
• Tofersen (BIIB067): Biogen/Ionis
• ION363: Ionis Pharmaceuticals
• NurOwn (MSC-NTF cells): Brainstorm Cell Therapeutics
• Reldesemtiv: Cytokinetics/Astellas Pharma
• Pegcetacoplan (APL-2): Apellis Pharmaceuticals
• Gold Nanocrystals/CNM-Au8: Clene Nanomedicine Biosciences
• AP-101: AL-S Pharma
• MN-166 (ibudilast): MediciNova

Discover more about therapies set to grab major Amyotrophic Lateral Sclerosis market share @ Amyotrophic Lateral Sclerosis Treatment Market
https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Amyotrophic Lateral Sclerosis Market Forecast:
• Potential Amyotrophic Lateral Sclerosis treatments are being developed in the mid- and late stages and could soon be released. The main participants in the market are Verdiperstat (Biohaven Pharmaceuticals), Masitinib (AB Science), Gold Nanocrystals/CNM-Au8 (Brainstorm-Cell Therapeutics), Tofersen/BIIB067 (Biogen/Ionis Pharmaceuticals), and others. This could lead to a rise in the market size in the upcoming years, helped along by a rise in the number of people with Amyotrophic Lateral Sclerosis diagnosis.
• RADICAVA (edaravone) has been an effective therapy for ALS. Recently, oral RADICAVA got approved in the US for the treatment of patients with ALS to increase the patient compliance.
• Most of the 7MM possess their own ALS registries, thereby providing a near precise country-wise number for diagnosed prevalent cases of the disease

Scope of the Amyotrophic Lateral Sclerosis Market Report:
• Study Period: 2022-2036
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Amyotrophic Lateral Sclerosis Companies: Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, Alector, GSK, NeuroSense Therapeutics, Biogen, Ionis Pharmaceuticals, Brainstorm Cell Therapeutics, Cytokinetics, Astellas Pharma, Apellis Pharmaceuticals, Clene Nanomedicine Biosciences, AL-S Pharma, MediciNova, Seelos Theraputics, Prilenia Therapeutics, AB Science, Eledon Pharmaceuticals, Revalesio Corporation, Biohaven Pharmaceuticals, UCB Pharma, Ra Pharmaceuticals, AI Therapeutics, and others, and others
• Key Amyotrophic Lateral Sclerosis Therapies: Engensis (VM202), SAR443820/DNL788, TPN-101, Latozinemab (AL001/GSK4527223), PrimeC, Tofersen (BIIB067), ION363, NurOwn (MSC-NTF cells), Reldesemtiv, Pegcetacoplan (APL-2), Gold Nanocrystals/CNM-Au8, AP-101, MN-166 (ibudilast), and others
• Amyotrophic Lateral Sclerosis Therapeutic Assessment: Amyotrophic Lateral Sclerosis current marketed and Amyotrophic Lateral Sclerosis emerging therapies
• Amyotrophic Lateral Sclerosis Market Dynamics: Amyotrophic Lateral Sclerosis market drivers and Amyotrophic Lateral Sclerosis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Amyotrophic Lateral Sclerosis Unmet Needs, KOL's views, Analyst's views, Amyotrophic Lateral Sclerosis Market Access and Reimbursement

To know more about Amyotrophic Lateral Sclerosis companies working in the treatment market, visit @ Amyotrophic Lateral Sclerosis Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

DelveInsight's report offers comprehensive insights, market analysis, and forecasts aiding leading companies in strategic decision-making for the Amyotrophic Lateral Sclerosis market landscape.
• Gain Competitive Edge in Indication Market : Understand the current landscape of the Amyotrophic Lateral Sclerosis market, including the competitive environment, key companies developing drugs for Amyotrophic Lateral Sclerosis, and their strategies. By analyzing market dynamics, treatment approaches, and emerging Amyotrophic Lateral Sclerosis therapies, stakeholders can identify opportunities to position themselves effectively, gaining a competitive edge over others.
• Identify Market Gaps and indication market opportunities : Analyzing epidemiological trends, country wise patient journeys and existing treatment practices can help in identifying gaps and opportunities within the Amyotrophic Lateral Sclerosis market. This involves recognizing areas where current Amyotrophic Lateral Sclerosis treatments may be insufficient or where there is an unmet need. The report is curated by taking account of various KOLs dealing with Amyotrophic Lateral Sclerosis. Identifying these gaps allows stakeholders to explore new therapeutic avenues, potentially leading to the development of novel treatments that address specific market needs and price their emerging products strategically to gain a competitive edge.
• Strategic decision making : Armed with insights from epidemiological and market forecasts, stakeholders can make informed and strategic decisions. This may involve deciding on research and development investments, portfolio expansion, pricing - reimbursement strategies, partnerships, or other strategic moves. Understanding the market dynamics enables stakeholders to align their goals with the prevailing trends and future projections.
• Plan RoadMap to Success : Through this report the leading companies can set short-term and long-term goals, define strategies for market penetration, and outline steps for product development or market expansion. A well-informed roadmap ensures that stakeholders navigate the complexities of the Amyotrophic Lateral Sclerosis market with clarity and purpose.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.